Answers are grounded in this paper and cite their sources.
Because of a unique combination of challenges facing human immunodeficiency virus vaccine developers, a number of traditional and novel vaccine designs are being evaluated essentially in parallel. Monomeric proteins, poxvirus vectors, peptides, and particle-based candidate vaccines have entered or will soon enter human trials. Other designs are at earlier stages of development. All candidates evaluated to date in phase I/II human trials have proven safe and immunogenic. One or more of the most promising designs will soon progress to 'test of concept' clinical trials to determine efficacy.
No takes yet. Share an insight, caveat, or question.
Margaret I. Johnston (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: